FindTrial
Sign In

Patient-reported outcomes

BEHAVIORAL4 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Université Catholique de Louvain, Center for International Blood and Marrow Transplant Research, German Society for Pediatric Oncology and Hematology GPOH gGmbH

Conditions

Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaBreast CancerChronic Lymphocytic LeukemiaChronic Myelogenous LeukemiaLymphomaMixed Phenotype Acute Leukemia

Phase 2

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Active, not recruitingNCT04904588
Center for International Blood and Marrow Transplant ResearchAcute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia +5
Start: 2021-09-30End: 2026-12-01Target: 300Updated: 2026-03-18
Nivolumab in Children and Adults With Nasopharyngeal Carcinoma
RecruitingNCT06019130
German Society for Pediatric Oncology and Hematology GPOH gGmbHNasopharyngeal Cancer, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms +1
Start: 2023-01-10End: 2028-01-09Target: 57Updated: 2024-05-16

Unknown Phase

Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
CompletedNCT01937052
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBreast Cancer
Start: 2012-05-09End: 2024-11-25Updated: 2024-12-13
QSPainRelief-patientCNS : Clinical Biomarkers of Nociception, Sedation and Cognition
NCT04742790
Université Catholique de LouvainPost-operative Pain
Start: 2021-03-15End: 2024-09-30Target: 180Updated: 2021-02-08

Related Papers

Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study
Blood2025-11-03
Living the recovery: One-year qol outcomes for patients receiving ptcy gvhd prophylaxis on the access clinical trial
Blood2025-11-03
ACCELERATE: A platform protocol to investigate post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis in patients with hematologic malignancies undergoing mismatched unrelated donor peripheral blood stem cell transplantation
Blood2025-11-03
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Journal of Clinical Oncology2025-06-1611 citations
OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Blood2024-11-052 citations
Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial
Blood2024-11-05
Post-transplant cyclophosphamide-based graft-<i>versus-</i>host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.
Journal of Clinical Oncology2024-06-014 citations
Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies
Blood2023-11-029 citations
Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer.
2023-06-016 citations
Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
Blood2022-11-155 citations
Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer.
2022-10-054 citations